Bethany Collins
Psychiatric/Mental Health · Lafayette, LANPI 1881060044
Payments from drug & device makers
Across 152 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$730
- Alkermes, Inc.$344
- Sunovion Pharmaceuticals Inc.$268
- Avanir Pharmaceuticals, Inc.$179
- Bausch Health US, LLC$149
- Takeda Pharmaceuticals U.S.A., Inc.$135
- plus $476 from 14 others
What the payments were for
- Food & beverage$2,281100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,281 in reported general payments places this provider in the 65th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 31 | $46,700 |
| RexultiBrexpiprazole | 16 | $25,476 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,004 |
| TrintellixVortioxetine Hydrobromide | 27 | $18,755 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $3,154 |
| Vilazodone Hcl | 30 | $1,844 |
| Quetiapine Fumarate | 117 | $1,771 |
| Aripiprazole | 68 | $1,616 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 124 | $1,566 |
| Olanzapine | 87 | $1,427 |
| Clonazepam | 239 | $1,336 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $1,316 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $1,049 |
| Doxepin Hcl | 28 | $848 |
| Bupropion XlBupropion Hcl | 55 | $843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $730 | $46,70031 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $33 | $25,47616 claims |
| Alkermes, Inc.Lybalvi | $344 | $22,00414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $135 | $18,75527 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $14 | $72426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lafayette
- Melissa GuilbeauLafayette$122K
- Bryant DronetteLafayette$17K
- Cinderella BroussardLafayette$14K
- Lore Lyndsey MoranLafayette$12K
- Danielle ThreattsLafayette$11K
- Seth WoodruffLafayette$10K
- Latonya WoodsLafayette$10K
- Laura KightLafayette$9K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.